Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial
- 28 April 2015
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 151 (2) , 309-318
Abstract
Progesterone receptor (PR) function, while essential in normal human breast, is also implicated in breast cancer risk. The two progesterone receptors, PRA and PRB, are co-expressed at equivalent levels in normal breast, but early in carcinogenesis normal levels of PRA:PRB are frequently disrupted, and predominance of one isoform, usually PRA, results. In model systems, PRA and PRB have different activities, and altering the PRA:PRB ratio in cell lines alters PR signaling. The purpose of this study was to determine whether hormonal or reproductive factors contribute to imbalanced PRA:PRB expression in breast tumors and the impact of PRA:PRB imbalance on disease outcome. The relative expression of PRA and PRB proteins was determined by dual immunofluorescence histochemistry in archival breast tumors and associations with clinical and reproductive history assessed. PRA:PRB expression was not influenced by reproductive factors, whereas exogenous hormone use (menopausal hormone treatment, MHT) favored PRB expression (p < 0.035). The PRA:PRB ratio may be a discriminator of response to endocrine therapy in the TransATAC sample collection, with high PRA:PRB ratio predicting earlier relapse for women on tamoxifen, but not anastrozole (mean lnPRA:PRB ratio; HR (95 % CI) tamoxifen 2.45 (1.20–4.99); p value 0.02; anastrozole 0.80 (0.36–1.78); p value 0.60). The results of this study show that PRA:PRB imbalance in breast cancers is not associated with lifetime endogenous endocrine and reproductive factors, but is associated with MHT use, and that PRA predominance can discriminate those women who will relapse earlier on tamoxifen treatment. These data support a role for imbalanced PRA:PRB expression in breast cancer progression and relative benefit from endocrine treatment.Keywords
Funding Information
- National Health and Medical Research Council (107222, 632908)
This publication has 34 references indexed in Scilit:
- Progesterone signalling in breast cancer: a neglected hormone coming into the limelightNature Reviews Cancer, 2013
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trialThe Lancet Oncology, 2010
- Overexpression of progesterone receptor A isoform in mice leads to endometrial hyperproliferation, hyperplasia and atypiaMolecular Human Reproduction, 2009
- Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal WomenNew England Journal of Medicine, 2009
- Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination TrialJournal of Clinical Oncology, 2008
- Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancerCurrent Medical Research and Opinion, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Effect of Progesterone Receptor A Predominance on Breast Cancer Cell Migration into Bone Marrow FibroblastsBreast Cancer Research and Treatment, 2004
- Biomarker investigations from the ATAC trial: the role of TA01Breast Cancer Research and Treatment, 2004
- Monoclonal Antibodies to Human Progesterone Receptor: Characterization by Biochemical and Immunohistochemical Techniques*Endocrinology, 1987